Source: Annual Congress 2010 - Nocturnal cardiology: chronic heart failure, acute chest syndrome, coronary artery disease and collagen vascular disease
Disease area: Pulmonary vascular diseases, Sleep and breathing disorders

Abstract

OSA is a risk factor for cardiovascular diseases. Brain natriuretic peptide (BNP) is a hormone secreted by the ventricles in response to volume or pressure overload. The aim of this study was to assess plasma NT-proBNP concentration (inactive form of BNP) in OSA pts before CPAP therapy and relations between hormone level and cardiovascular complications. We studied 914 OSA pts (74.9% of males), mean age – 56.3±10.1 years, with obesity (BMI – 34.4±6.5 kg/m²) and moderate or severe disease (AHI – 38.6±21.5). Increased plasma NT-proBNP (> 125 pg/ml) was found in 238 subjects (26%). Comparison of OSA subjects with normal and higher NT-proBNP is shown in table.

Variable	Higher NT-proBNP (n= 238)	Normal NT-proBNP (n=676)	p
Age (years)	61.7±8.7	54.4±10	p<0.0001
BMI (kg/m2)	34.9±7.4	34.2±6.2	NS
AHI (n/h)	37.1±20.5	39.1±21.8	NS
Mean SaO2 (%)	90.2±7.8	90.8±5.4	NS
T90 (%)	28.6±30.5	27.1±28.6	NS
Coronary artery disease (CAD) (n/% of pts)	99 (41.6%)	114 (16.9%)	p<0.0001
Atrial fibrillation (AF) (n/% of pts)	48 (20.2%)	23 (3.4%)	p<0.0001
Heart failure (HF) (n/% of pts)	73 (30.7%)	34 (5%)	p<0.0001
Arterial hypertension (AH) (n/% of pts)	195 (81.9%)	471 (69.7%)	p=0.002

Multiple linear regression analysis confirmed significant correlation between NT-proBNP and Heart Failure (β=0.39, p<0.0001), Atrial Fibrillation (β=0.23, p<0.0001), FEV₁ (% of predicted) (β= -0.17, p=0.009) and age (β=0.1, p<0.004).
Conclusions: Increased plasma NT-proBNP concentration in OSA subjects was related to Heart Failure, Atrial Fibrillation, lower FEV₁ and older age.

Rating:

Share or cite this content

Citations should be made in the following way:
R. Plywaczewski, L. Jonczak, B. Kazanecka, P. Bielen, D. Gorecka, P. Sliwinski (Warsaw, Poland). Relationship between plasma NT-proBNP level and cardiovascular complications in obstructive sleep apnoea (OSA) patients. Eur Respir J 2010; 36: Suppl. 54, 916

Member's Comments

No comment yet.

Related content which might interest you: Relationship between NT-proBNP plasma level and nocturia in obstructive sleep apnoea (OSA) patients Source: Annual Congress 2007 - Systemic effects of obstructive sleep apnoea Year: 2007 Relationship between NT-proBNP level, echocardiographic parameters and cardiovascular diseases in patients with obstructive sleep apnoea (OSA) Source: Annual Congress 2012 - Physiology, obesity and the downstream effects of OSA Year: 2012 Relations between cystatin C plasma concentration and cardiovascular complications in patients with obstructive sleep apnoea (OSA) Source: Annual Congress 2012 - Metabolic and cardiovascular consequences of OSA I Year: 2012 Cardiovascular diseases are responsible for increased plasma NT-proBNP level in obstructive sleep apnoea (OSA) patients Source: Annual Congress 2012 - Physiology, obesity and the downstream effects of OSA Year: 2012 Cardiac troponin I levels and relationship with cardiovascular morbidity in patients with obstructive sleep apnea syndrome Source: Eur Respir J 2005; 26: Suppl. 49, 38s Year: 2005 Comparison of plasma NT-proBNP level in overlap syndrome (obstructive sleep apnoea + chronic obstructive pulmonary disease) and obstructive sleep apnoea (OSA) Source: Annual Congress 2008 - Control of breathing and respiratory disorders during sleep Year: 2008 Influence of body weight on plasma NT-proBNP in obstructive sleep apnoea (OSA) patients Source: Annual Congress 2007 - Cardiovascular and respiratory control in obstructive sleep apnoea Year: 2007 BNP or VEGF levels do not predict disease severity in obstructive sleep apnoea syndrome (OSAS) Source: Eur Respir J 2005; 26: Suppl. 49, 40s Year: 2005 Correlations between cardiovascular diseases and diabetes in obstructive sleep apnoea (OSA) Source: Annual Congress 2012 - Metabolic and cardiovascular consequences of OSA I Year: 2012 NT-proBNP in obstructive sleep apnoea (OSA) Source: Eur Respir J 2006; 28: Suppl. 50, 415s Year: 2006 C-reactive protein (CRP) levels in obstructive sleep apnea (OSA) patients and relation to severity of OSA Source: Annual Congress 2011 - Cardiometabolic and neurocognitive changes in obstructive sleep apnoea Year: 2011 Physical activity in obstructive sleep apnea (OSA) patients with high cardiovascular risk Source: Annual Congress 2010 - Obesity: positive effects of bariatric surgery and exercise Year: 2010 Prevalence and predictors of arrhythmia in patients with obstructive sleep apnea (OSA) Source: Annual Congress 2011 - Obstructive sleep apnoea: the heart and the brain Year: 2011 Prevalence of stroke in obstructive sleep apnoea (OSA) patients Source: Eur Respir J 2007; 30: Suppl. 51, 331s Year: 2007 Relationship between age and cardiovascular diseases (CVD) in obstructive sleep apnoea (OSA) Source: Annual Congress 2008 - Weight control and comorbidity in obstructive sleep apnoea Year: 2008 C-reactive protein (CRP) and prevalence of cardiovascular diseases in obstructive sleep apnoea (OSA) patients Source: Annual Congress 2007 - Sleep apnoea in cardiorespiratory disorders Year: 2007 Impaired glucose tolerance and other cardiovascular risk factors in patients with obstructive sleep apnea syndrome (OSAS) Source: Annual Congress 2009 - Systemic consequences of sleep-disordered breathing Year: 2009 Correlations between severity of nocturnal hypoxemia and level of Galectin-3 in obstructive sleep apnea patients Source: International Congress 2019 – Consequences of sleep-disordered breathing from molecular and clinical points of view Year: 2019 Prevalence of cardiorespiratory disease increase with increasing severity of obstructive sleep apnoea (OSA) Source: Eur Respir J 2002; 20: Suppl. 38, 322s Year: 2002 Increased plasma haemoglobin A1c (HbA1c) concentration and cardiovascular complications in obstructive sleep apnoea (OSA) patients with and without diabetes Source: Annual Congress 2009 - Systemic consequences of sleep-disordered breathing Year: 2009